Oculis Raises $110 Million to Accelerate its Development

The Swiss-Icelandic ophthalmology company Oculis, based in Zug with its operational headquarters in Lausanne, has completed an oversubscribed capital increase of $110 million. This is its second fundraising round exceeding $100 million in less than a year, following the one in February.

Net proceeds from the financing will be used to advance and accelerate the development of its novel neuroprotective clinical candidate, Privosegtor in acute optic neuritis (AON) and non-arteritic anterior ischemic optic neuropathy (NAION), as well as for working capital and general corporate purposes.

The biopharmaceutical company’s highly differentiated late-stage clinical pipeline includes three core product candidates: Privosegtor, a neuroprotective candidate in the PIONEER program which consists of studies intended to support registration for treatment in optic neuropathies like acute optic neuritis (AON) and non-arteritic anterior ischemic optic neuropathy (NAION), with potentially broad clinical applications in various other neuro-ophthalmic and neurological diseases; OCS-01, an eye drop in pivotal registration studies, aiming to become the first non-invasive topical treatment for diabetic macular edema (DME); and Licaminlimab, a novel, topical anti-TNFα in Phase 2, which is being developed with a genotype-based approach to drive personalized medicine in dry eye disease (DED).


➡️ Source: Press Release